4521 — Kaken Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapNeutral

Annual income statement for Kaken Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	—	—	—	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	76,034	72,984	72,044	94,035	76,871
Cost of Revenue
Gross Profit	41,576	39,556	38,539	58,533	39,992
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	62,830	66,898	62,698	75,095	78,632
Operating Profit	13,204	6,086	9,346	18,940	-1,761
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,885	6,817	9,796	19,435	2,313
Provision for Income Taxes
Net Income After Taxes	9,549	5,440	8,026	13,945	2,145
Net Income Before Extraordinary Items
Net Income	9,549	5,440	8,026	13,945	2,145
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,549	5,440	8,025	13,945	2,144
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	318	186	220	407	51.3
Dividends per Share
Special Dividends per Share